Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 13

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 13
---
 stock. Any significant downward pressure on the price of our common stock as the selling stockholders sell their shares of our common stock could encourage other stockholders to sell as well as short sales by the selling stockholders or others. Any such short sales could place further downward pressure on the price of our common stock. There is no assurance that we will be able to continue to comply with Nasdaq’s minimum bid price requirement, and as a result our common stock may become delisted, which could have a material adverse effect on the liquidity of our common stock and our ability to raise capital. To maintain the listing of our shares of common stock on the Nasdaq, our common stock must maintain a minimum bid price of $1.00 as set forth in Nasdaq Rule 5550(a)(2). If the closing bid price of our common stock is below $1.00 for 30 consecutive trading days, Nasdaq will send a deficiency notice to us, advising us that we have been afforded a “compliance period” of 180 calendar days to regain compliance with the applicable requirements. The closing bid price for our common stock fell below the minimum $1.00 per share required for continued listing on Nasdaq pursuant to Rule 5550(a)(2), starting on April 2, 2025. There is no assurance that we will be able to meet Nasdaq’s listing requirements or comply with the requisite Nasdaq requirements to maintain our listing of common stock on Nasdaq. If Nasdaq delists our securities from trading on its exchange and we are not able to list our securities on Nasdaq or any other national securities exchange, we could face significant material adverse consequences, including:

| • |     | a limited availability of market quotations for our common stock; |

| • |     | reduced liquidity for our common stock; |

| • |     | a determination that our common stock is a “penny stock,” which will require brokers trading in our                                                           
 common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |

| • |     | a limited amount of news and analyst coverage for us; |

| • |     | a decreased ability to issue additional securities or obtain additional financing in the future; and |

| • |     | the incurring of additional costs under state blue sky laws in connection with any sales of our securities. |

If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the